Welcome to our dedicated page for NEUROCRINE BIOSCIENCES SEC filings (Ticker: NBIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Neurocrine Biosciences Inc. filings document the regulatory record of a commercial biopharmaceutical company developing and selling treatments for neurological, psychiatric, endocrine and immunological disorders. Its 8-K reports cover operating and financial results, product-sales disclosures, clinical or regulatory updates, material agreements, capital-structure matters and executive or employment-related governance events.
Proxy filings describe board matters, shareholder voting items, executive compensation, equity awards and pay-versus-performance disclosures. The filing record also includes formal disclosures related to INGREZZA, CRENESSITY and the company's pipeline, as well as risk, governance and transaction-related disclosure categories relevant to its public-company status.
Onyia Jude reported multiple insider transaction types in a Form 4 filing for NBIX. The filing lists transactions totaling 115,756 shares at a weighted average price of $124.02 per share. Following the reported transactions, holdings were 5,380 shares.
BENEVICH ERIC reported multiple insider transaction types in a Form 4 filing for NBIX. The filing lists transactions totaling 83,590 shares at a weighted average price of $124.03 per share. Following the reported transactions, holdings were 3,924 shares.
Cooke Julie reported multiple insider transaction types in a Form 4 filing for NBIX. The filing lists transactions totaling 58,116 shares at a weighted average price of $124.02 per share. Following the reported transactions, holdings were 2,802 shares.
Lippoldt Darin reported multiple insider transaction types in a Form 4 filing for NBIX. The filing lists transactions totaling 71,708 shares at a weighted average price of $124.00 per share. Following the reported transactions, holdings were 4,036 shares.
Delaet Ingrid reported multiple insider transaction types in a Form 4 filing for NBIX. The filing lists transactions totaling 78,494 shares at a weighted average price of $124.05 per share. Following the reported transactions, holdings were 2,802 shares.
GORMAN KEVIN CHARLES reported multiple insider transaction types in a Form 4 filing for NBIX. The filing lists transactions totaling 125,991 shares at a weighted average price of $124.12 per share. Following the reported transactions, holdings were 11,208 shares.
Keswani Sanjay Chandru reported acquisition or exercise transactions in this Form 4 filing.
Neurocrine Biosciences’ Chief Medical Officer receives new equity awards. Sanjay Chandru Keswani was granted a stock option covering 35,827 shares of common stock on February 13, 2026. The option vests monthly, with 1/48 of the shares vesting starting March 13, 2026.
He was also granted 6,285 Restricted Stock Units on the same date. These RSUs vest in four equal annual installments on February 13 of 2027, 2028, 2029, and 2030, with each RSU representing one share of common stock upon settlement.
Neurocrine Biosciences reports its full-year 2025 results and business overview, highlighting strong growth from key neuroscience drugs. INGREZZA net product sales reached $2.51 billion in 2025, up from $2.31 billion in 2024 and $1.84 billion in 2023, while CRENESSITY generated $301.2 million in its first full launch year.
The company is expanding a U.S. sales force of about 600 people and plans to add more INGREZZA and CRENESSITY representatives by the end of the first quarter of 2026. Late-stage programs include Phase 3 trials for osavampator in major depressive disorder and direclidine in schizophrenia, with initial topline data expected in 2027.
Neurocrine emphasizes a broad pipeline across psychiatry, neurology, endocrinology and metabolic disease, backed by extensive patent protection. The company also discloses a civil investigative demand from the U.S. Department of Justice related to INGREZZA sales and marketing, noting it is cooperating and that the ultimate outcome is uncertain.
Neurocrine Biosciences reported strong growth for the fourth quarter and full year 2025. Total revenues reached $805.5 million in Q4 and $2.86 billion for 2025, up from $2.36 billion in 2024, driven mainly by its neurology portfolio.
INGREZZA generated net product sales of $657.5 million in Q4 and $2.51 billion for 2025, with single‑digit growth as prescription volumes rose but were partially offset by lower net price from new formulary investments. CRENESSITY contributed $135.3 million in Q4 and $301.2 million for 2025 as a new growth driver.
GAAP net income increased to $153.7 million in Q4 and $478.6 million for 2025, while Non‑GAAP net income was $194.6 million in Q4 and $654.5 million for the year. Cash, cash equivalents, and marketable securities totaled $2.54 billion at December 31, 2025, supporting heavy R&D and commercial investment.
For 2026, the company guides INGREZZA net product sales to $2.7–$2.8 billion, and plans GAAP R&D spending of $1.2–$1.25 billion and GAAP SG&A of $1.38–$1.40 billion as it advances Phase 3 programs in depression and schizophrenia and continues the CRENESSITY launch.
Neurocrine Biosciences Chief Corp. Affairs Officer David W. Boyer reported routine equity compensation activity. On January 31, 2026, 2,096 restricted stock units converted into the same number of Neurocrine Biosciences common shares at $0 exercise price.
To cover tax withholding on this RSU vesting, the company withheld 1,189 shares of common stock at $136.06 per share, and no shares were sold in the market. Following these transactions, Boyer directly owned 4,713 shares of Neurocrine Biosciences common stock. The underlying RSU grant, originally awarded on January 31, 2022, completed its final vesting tranche of 2,096 shares on the same date.